# Emergent BioSolutions

supplies anthrax vaccine and smallpox medical countermeasures under direct government delivery contracts, including a contract with the US Department of War and international government partners.


Source: https://cn.bioecon.ru/companies/emergent-biosolutions/
Updated: 2026-08-15

- 国家: United States
- 代码: NYSE:EBS

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 2025年$7.43亿 | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| 员工人数 | 850名员工 | https://www.emergentbiosolutions.com/wp-content/uploads/2026/08/EBSI-Corporate-Fact-Sheet-8-11-26.pdf |
| 融资 | 针对ACAM2000的合同修订金额$5270万(2026年6月) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| 融资 | 针对CYFENDUS的合同变更金额为$3000万（2025年9月） | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-contract-modification-valued, https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award, https://investors.emergentbiosolutions.com/node/23881/pdf, https://synapse.patsnap.com/article/emergent-biosolutions-secures-250m2B-in-contracts-for-key-medical-supplies-to-us-government, https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/pressrelease_010825.htm, https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/exhibit108mod2-biothraxp.htm |
| 融资 | 2026年3月获得CNJ-016合同，金额$5400万 | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-over-60-million-new-contract-award |
| 融资 | 2024年为BioThrax签订的五年合同,金额$2.358亿 | https://www.fiercepharma.com/pharma/emergent-biosolutions-bags-250m-contract-expansions-bulk-us-medical-countermeasure-supply |
| 生产基地 | 加拿大温尼伯 | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| 生产基地 | 密歇根州兰辛(Lansing) | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| 生产基地 | 美国马里兰州巴尔的摩（Bayview和Camden） | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview, https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| 生产基地 | 美国马萨诸塞州坎顿（Canton） | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| 生产基地 | 密西西比州哈蒂斯堡（Hattiesburg） | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| 生产基地 | Rockville, Maryland | https://www.emergentbiosolutions.com/wp-content/uploads/2024/05/EBSI_2023_ESG_Report_V5.pdf |
| 认证 | Baltimore Bayview设施获No Action Indicated(NAI)状态(2024年3月) | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-nai-status-baltimore-bayview |
| 认证 | Camden工厂获"建议自愿整改"（VAI）状态（2023年10月） | https://www.sec.gov/Archives/edgar/data/1367644/000136764423000169/ebs-20231005.htm |
| 监管批准 | CYFENDUS 获得 FDA 批准（2023年7月） | https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-receives-us-fda-approval-drug-product, https://investors.emergentbiosolutions.com/node/23881/pdf, https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |
| 监管批准 | FDA批准在温尼伯生产raxibacumab的sBLA申请（2025年12月） | https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm |

独立来源: fiercepharma.com, sec.gov, synapse.patsnap.com

## 技术

- [国防生物经济](https://cn.bioecon.ru/technology/defense-bioeconomy/)